Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer
Hinova Pharmaceuticals Inc. has registered a Phase 3, randomized, double-blind, placebo-controlled study of Deutenzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with high-risk biochemical recurrence of prostate cancer. The study plans to enroll 1044 participants and is expected to start on October 31, 2026, with primary completion projected for December 31, 2029.
-
Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori
The study, led by Onconic Therapeutics Inc., plans to enroll 414 participants and begin recruiting on November 1, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial to evaluate the efficacy and safety of JP-1366-based triple therapy in H. Pylori-positive subjects.
-
Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention
Merck Sharp & Dohme LLC has registered a Phase 3, randomized, double-blind, placebo-controlled study (ENHANCE-3) to evaluate ensifentrine (MK-5884) for preventing moderate and severe COPD exacerbations. The trial plans to enroll 2136 participants, begin on October 23, 2026, and reach primary completion on April 29, 2029.
-
Sanofi posts results of Phase 3 itepekimab trial in COPD
The Phase 3 study, NCT04701983 (AERIFY-1), enrolled 1127 participants and completed primary data collection on April 11, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
United Therapeutics posts results of Phase 3 TETON-2 inhaled treprostinil study
The study enrolled 597 participants and completed primary data collection on June 30, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
ACADIA posts results of Phase 3 carbetocin nasal spray trial in Prader-Willi syndrome
The study, completed in August 2025, enrolled 175 participants and evaluated carbetocin nasal spray versus placebo over 12 weeks. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
Vertex posts results of Phase 3 ELX/TEZ/IVA study in infants
Vertex Pharmaceuticals Incorporated posted results of a completed Phase 3, open-label study evaluating the pharmacokinetics, safety, tolerability, pharmacodynamics, and efficacy of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants and began on June 27, 2023, with primary completion on September 4, 2025.
-
Roche posts Phase 3 results for obinutuzumab in childhood nephrotic syndrome
Hoffmann-La Roche posted results on October 14, 2026 for its INShore trial of obinutuzumab against mycophenolate mofetil. The record lists sustained complete remission at Week 52 in 95.5% of 44 participants on obinutuzumab and 73.2% of 41 on mycophenolate mofetil.
-
Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis
The study plans to enroll 230 participants and is expected to start in November 2026. It aims to evaluate the efficacy and safety of lebrikizumab for up to 32 weeks in adults and adolescents with moderate-to-severe face and neck atopic dermatitis who also have moderate-to-severe AD elsewhere and need systemic therapy.
-
Ultragenyx posts results of Phase 3 DTX401 trial in Glycogen Storage Disease Type Ia
The study enrolled 52 participants and completed primary data collection on February 20, 2024. It evaluated DTX401's ability to reduce or eliminate dependence on exogenous glucose replacement therapy and to improve glucose control quality.
-
Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome
The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.
-
AbbVie presents Phase 3 AFFIRM data showing endoscopic remission with SKYRIZI in Crohn's disease
The study reported that 35.8% of patients achieved endoscopic remission and 36.6% achieved ulcer-free endoscopy after subcutaneous SKYRIZI versus 10.2% and 10.2% with placebo. Safety findings through week 24 were consistent with the known safety profile of risankizumab, with no new safety signals.